Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. ACOR Peers
See (ACOR) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ACOR | $0.66 | -24.02% | 821K | -0.00 | -$203.57 | N/A |
| ZTS | $154.96 | -2.42% | 69B | 27.77 | $5.58 | +1.20% |
| TAK | $14.68 | -1.08% | 46.2B | 63.85 | $0.23 | +4.01% |
| HLN | $9.96 | -1.48% | 44.7B | 23.14 | $0.43 | +1.68% |
| TEVA | $16.40 | -0.76% | 18.8B | -14.27 | -$1.15 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| NBIX | $133.46 | -1.08% | 13.2B | 45.25 | $2.95 | N/A |
| RDY | $14.51 | -1.09% | 12.1B | 18.38 | $0.79 | +0.66% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| VTRS | $9.12 | -1.41% | 10.7B | -2.87 | -$3.18 | +6.54% |
Stock Comparison
ACOR vs ZTS Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, ZTS has a market cap of 69B. Regarding current trading prices, ACOR is priced at $0.66, while ZTS trades at $154.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas ZTS's P/E ratio is 27.77. In terms of profitability, ACOR's ROE is +1.43%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, ACOR is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs TAK Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, TAK has a market cap of 46.2B. Regarding current trading prices, ACOR is priced at $0.66, while TAK trades at $14.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas TAK's P/E ratio is 63.85. In terms of profitability, ACOR's ROE is +1.43%, compared to TAK's ROE of +0.04%. Regarding short-term risk, ACOR is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs HLN Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, HLN has a market cap of 44.7B. Regarding current trading prices, ACOR is priced at $0.66, while HLN trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas HLN's P/E ratio is 23.14. In terms of profitability, ACOR's ROE is +1.43%, compared to HLN's ROE of +0.09%. Regarding short-term risk, ACOR is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs TEVA Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, TEVA has a market cap of 18.8B. Regarding current trading prices, ACOR is priced at $0.66, while TEVA trades at $16.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas TEVA's P/E ratio is -14.27. In terms of profitability, ACOR's ROE is +1.43%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, ACOR is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs ITCI Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ACOR is priced at $0.66, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ACOR's ROE is +1.43%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, ACOR is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs NBIX Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, NBIX has a market cap of 13.2B. Regarding current trading prices, ACOR is priced at $0.66, while NBIX trades at $133.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas NBIX's P/E ratio is 45.25. In terms of profitability, ACOR's ROE is +1.43%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, ACOR is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs RDY Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, RDY has a market cap of 12.1B. Regarding current trading prices, ACOR is priced at $0.66, while RDY trades at $14.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas RDY's P/E ratio is 18.38. In terms of profitability, ACOR's ROE is +1.43%, compared to RDY's ROE of +0.18%. Regarding short-term risk, ACOR is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs CTLT Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ACOR is priced at $0.66, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ACOR's ROE is +1.43%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, ACOR is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs VTRS Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, VTRS has a market cap of 10.7B. Regarding current trading prices, ACOR is priced at $0.66, while VTRS trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas VTRS's P/E ratio is -2.87. In terms of profitability, ACOR's ROE is +1.43%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, ACOR is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs ELAN Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, ELAN has a market cap of 7.4B. Regarding current trading prices, ACOR is priced at $0.66, while ELAN trades at $14.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas ELAN's P/E ratio is 19.87. In terms of profitability, ACOR's ROE is +1.43%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, ACOR is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs RGC Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, RGC has a market cap of 7.3B. Regarding current trading prices, ACOR is priced at $0.66, while RGC trades at $14.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas RGC's P/E ratio is -1470.00. In terms of profitability, ACOR's ROE is +1.43%, compared to RGC's ROE of -0.25%. Regarding short-term risk, ACOR is more volatile compared to RGC. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs LNTH Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, LNTH has a market cap of 5.6B. Regarding current trading prices, ACOR is priced at $0.66, while LNTH trades at $81.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas LNTH's P/E ratio is 22.28. In terms of profitability, ACOR's ROE is +1.43%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ACOR is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs AMRX Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, AMRX has a market cap of 3.9B. Regarding current trading prices, ACOR is priced at $0.66, while AMRX trades at $8.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas AMRX's P/E ratio is -208.12. In terms of profitability, ACOR's ROE is +1.43%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, ACOR is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs PRGO Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, PRGO has a market cap of 3.8B. Regarding current trading prices, ACOR is priced at $0.66, while PRGO trades at $27.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas PRGO's P/E ratio is -22.95. In terms of profitability, ACOR's ROE is +1.43%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, ACOR is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs HCM Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, HCM has a market cap of 2.8B. Regarding current trading prices, ACOR is priced at $0.66, while HCM trades at $16.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas HCM's P/E ratio is 80.15. In terms of profitability, ACOR's ROE is +1.43%, compared to HCM's ROE of +0.05%. Regarding short-term risk, ACOR is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs ALVO Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, ALVO has a market cap of 2.6B. Regarding current trading prices, ACOR is priced at $0.66, while ALVO trades at $8.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas ALVO's P/E ratio is 23.05. In terms of profitability, ACOR's ROE is +1.43%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, ACOR is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs BHC Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, ACOR is priced at $0.66, while BHC trades at $6.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas BHC's P/E ratio is -53.54. In terms of profitability, ACOR's ROE is +1.43%, compared to BHC's ROE of +0.05%. Regarding short-term risk, ACOR is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs DCPH Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ACOR is priced at $0.66, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ACOR's ROE is +1.43%, compared to DCPH's ROE of -0.28%. Regarding short-term risk, ACOR is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs ALVOW Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, ALVOW has a market cap of 2.2B. Regarding current trading prices, ACOR is priced at $0.66, while ALVOW trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas ALVOW's P/E ratio is N/A. In terms of profitability, ACOR's ROE is +1.43%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, ACOR is more volatile compared to ALVOW. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs INDV Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, INDV has a market cap of 1.9B. Regarding current trading prices, ACOR is priced at $0.66, while INDV trades at $15.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas INDV's P/E ratio is -309.80. In terms of profitability, ACOR's ROE is +1.43%, compared to INDV's ROE of -0.01%. Regarding short-term risk, ACOR is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs EMBCV Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ACOR is priced at $0.66, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ACOR's ROE is +1.43%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, ACOR is more volatile compared to EMBCV. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs SUPN Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, SUPN has a market cap of 1.9B. Regarding current trading prices, ACOR is priced at $0.66, while SUPN trades at $33.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas SUPN's P/E ratio is 29.82. In terms of profitability, ACOR's ROE is +1.43%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, ACOR is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs BGM Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, BGM has a market cap of 1.7B. Regarding current trading prices, ACOR is priced at $0.66, while BGM trades at $9.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas BGM's P/E ratio is -46.65. In terms of profitability, ACOR's ROE is +1.43%, compared to BGM's ROE of -0.03%. Regarding short-term risk, ACOR is more volatile compared to BGM. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs TARO Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ACOR is priced at $0.66, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas TARO's P/E ratio is 30.05. In terms of profitability, ACOR's ROE is +1.43%, compared to TARO's ROE of +0.02%. Regarding short-term risk, ACOR is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs EVO Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, EVO has a market cap of 1.4B. Regarding current trading prices, ACOR is priced at $0.66, while EVO trades at $4.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas EVO's P/E ratio is -5.90. In terms of profitability, ACOR's ROE is +1.43%, compared to EVO's ROE of -0.22%. Regarding short-term risk, ACOR is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs ANIP Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, ANIP has a market cap of 1.4B. Regarding current trading prices, ACOR is priced at $0.66, while ANIP trades at $64.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas ANIP's P/E ratio is -55.07. In terms of profitability, ACOR's ROE is +1.43%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, ACOR is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs HROW Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, HROW has a market cap of 1.3B. Regarding current trading prices, ACOR is priced at $0.66, while HROW trades at $34.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas HROW's P/E ratio is -57.18. In terms of profitability, ACOR's ROE is +1.43%, compared to HROW's ROE of -0.36%. Regarding short-term risk, ACOR is more volatile compared to HROW. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs DVAX Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, DVAX has a market cap of 1.3B. Regarding current trading prices, ACOR is priced at $0.66, while DVAX trades at $10.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas DVAX's P/E ratio is -21.14. In terms of profitability, ACOR's ROE is +1.43%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ACOR is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs FLXN Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, FLXN has a market cap of 1.3B. Regarding current trading prices, ACOR is priced at $0.66, while FLXN trades at $25.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas FLXN's P/E ratio is N/A. In terms of profitability, ACOR's ROE is +1.43%, compared to FLXN's ROE of +6.19%. Regarding short-term risk, ACOR is more volatile compared to FLXN. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs PAHC Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, PAHC has a market cap of 1.2B. Regarding current trading prices, ACOR is priced at $0.66, while PAHC trades at $30.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas PAHC's P/E ratio is 39.49. In terms of profitability, ACOR's ROE is +1.43%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, ACOR is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs PCRX Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, PCRX has a market cap of 1.1B. Regarding current trading prices, ACOR is priced at $0.66, while PCRX trades at $22.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas PCRX's P/E ratio is -10.22. In terms of profitability, ACOR's ROE is +1.43%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, ACOR is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs COLL Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, COLL has a market cap of 1B. Regarding current trading prices, ACOR is priced at $0.66, while COLL trades at $32.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas COLL's P/E ratio is 26.64. In terms of profitability, ACOR's ROE is +1.43%, compared to COLL's ROE of +0.19%. Regarding short-term risk, ACOR is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs AMPH Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, AMPH has a market cap of 1B. Regarding current trading prices, ACOR is priced at $0.66, while AMPH trades at $21.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas AMPH's P/E ratio is 7.84. In terms of profitability, ACOR's ROE is +1.43%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, ACOR is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs AVDL Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, AVDL has a market cap of 932.1M. Regarding current trading prices, ACOR is priced at $0.66, while AVDL trades at $9.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas AVDL's P/E ratio is -37.00. In terms of profitability, ACOR's ROE is +1.43%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, ACOR is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs PETQ Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ACOR is priced at $0.66, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ACOR's ROE is +1.43%, compared to PETQ's ROE of +0.05%. Regarding short-term risk, ACOR is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs CRON Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, CRON has a market cap of 805.5M. Regarding current trading prices, ACOR is priced at $0.66, while CRON trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas CRON's P/E ratio is 14.93. In terms of profitability, ACOR's ROE is +1.43%, compared to CRON's ROE of +0.05%. Regarding short-term risk, ACOR is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs EMBC Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, EMBC has a market cap of 611.9M. Regarding current trading prices, ACOR is priced at $0.66, while EMBC trades at $10.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas EMBC's P/E ratio is 11.76. In terms of profitability, ACOR's ROE is +1.43%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, ACOR is more volatile compared to EMBC. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs EOLS Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, EOLS has a market cap of 611.2M. Regarding current trading prices, ACOR is priced at $0.66, while EOLS trades at $9.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas EOLS's P/E ratio is -10.65. In terms of profitability, ACOR's ROE is +1.43%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, ACOR is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs TLRY Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, TLRY has a market cap of 603.8M. Regarding current trading prices, ACOR is priced at $0.66, while TLRY trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas TLRY's P/E ratio is -0.53. In terms of profitability, ACOR's ROE is +1.43%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, ACOR is more volatile compared to TLRY. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs BDSI Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ACOR is priced at $0.66, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ACOR's ROE is +1.43%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ACOR is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs ORGO Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, ORGO has a market cap of 544.8M. Regarding current trading prices, ACOR is priced at $0.66, while ORGO trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas ORGO's P/E ratio is -26.84. In terms of profitability, ACOR's ROE is +1.43%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, ACOR is more volatile compared to ORGO. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs SIGA Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, SIGA has a market cap of 483.3M. Regarding current trading prices, ACOR is priced at $0.66, while SIGA trades at $6.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas SIGA's P/E ratio is 10.10. In terms of profitability, ACOR's ROE is +1.43%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, ACOR is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs KMDA Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, KMDA has a market cap of 447.4M. Regarding current trading prices, ACOR is priced at $0.66, while KMDA trades at $7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas KMDA's P/E ratio is 27.79. In terms of profitability, ACOR's ROE is +1.43%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, ACOR is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs EBS Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, EBS has a market cap of 398.9M. Regarding current trading prices, ACOR is priced at $0.66, while EBS trades at $7.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas EBS's P/E ratio is -2.85. In terms of profitability, ACOR's ROE is +1.43%, compared to EBS's ROE of -0.27%. Regarding short-term risk, ACOR is more volatile compared to EBS. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs AQST Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, AQST has a market cap of 397.3M. Regarding current trading prices, ACOR is priced at $0.66, while AQST trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas AQST's P/E ratio is -6.90. In terms of profitability, ACOR's ROE is +1.43%, compared to AQST's ROE of +1.07%. Regarding short-term risk, ACOR is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs SNDL Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, SNDL has a market cap of 353.7M. Regarding current trading prices, ACOR is priced at $0.66, while SNDL trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas SNDL's P/E ratio is -4.58. In terms of profitability, ACOR's ROE is +1.43%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, ACOR is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs LFCR Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, LFCR has a market cap of 306.6M. Regarding current trading prices, ACOR is priced at $0.66, while LFCR trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas LFCR's P/E ratio is -5.63. In terms of profitability, ACOR's ROE is +1.43%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, ACOR is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs ALIM Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ACOR is priced at $0.66, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ACOR's ROE is +1.43%, compared to ALIM's ROE of -0.32%. Regarding short-term risk, ACOR is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs ZYBT Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, ZYBT has a market cap of 275.3M. Regarding current trading prices, ACOR is priced at $0.66, while ZYBT trades at $5.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas ZYBT's P/E ratio is 96.83. In terms of profitability, ACOR's ROE is +1.43%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, ACOR is more volatile compared to ZYBT. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs LNDC Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ACOR is priced at $0.66, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ACOR's ROE is +1.43%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, ACOR is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs TKNO Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, TKNO has a market cap of 257.1M. Regarding current trading prices, ACOR is priced at $0.66, while TKNO trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas TKNO's P/E ratio is -10.93. In terms of profitability, ACOR's ROE is +1.43%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, ACOR is more volatile compared to TKNO. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs ACB Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, ACB has a market cap of 252.5M. Regarding current trading prices, ACOR is priced at $0.66, while ACB trades at $4.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas ACB's P/E ratio is 20.41. In terms of profitability, ACOR's ROE is +1.43%, compared to ACB's ROE of +0.00%. Regarding short-term risk, ACOR is more volatile compared to ACB. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs ESPR Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, ESPR has a market cap of 236.8M. Regarding current trading prices, ACOR is priced at $0.66, while ESPR trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas ESPR's P/E ratio is -1.41. In terms of profitability, ACOR's ROE is +1.43%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, ACOR is more volatile compared to ESPR. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs CGC Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, CGC has a market cap of 235.7M. Regarding current trading prices, ACOR is priced at $0.66, while CGC trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas CGC's P/E ratio is -0.28. In terms of profitability, ACOR's ROE is +1.43%, compared to CGC's ROE of -1.13%. Regarding short-term risk, ACOR is more volatile compared to CGC. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs TYHT Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ACOR is priced at $0.66, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ACOR's ROE is +1.43%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, ACOR is more volatile compared to TYHT. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs SXTC Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, SXTC has a market cap of 203M. Regarding current trading prices, ACOR is priced at $0.66, while SXTC trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas SXTC's P/E ratio is 0.01. In terms of profitability, ACOR's ROE is +1.43%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, ACOR is more volatile compared to SXTC. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs OGI Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, OGI has a market cap of 194.1M. Regarding current trading prices, ACOR is priced at $0.66, while OGI trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas OGI's P/E ratio is 11.15. In terms of profitability, ACOR's ROE is +1.43%, compared to OGI's ROE of +0.05%. Regarding short-term risk, ACOR is more volatile compared to OGI. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs REPH Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ACOR is priced at $0.66, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas REPH's P/E ratio is -8.04. In terms of profitability, ACOR's ROE is +1.43%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ACOR is more volatile compared to REPH. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs DERM Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, DERM has a market cap of 166.8M. Regarding current trading prices, ACOR is priced at $0.66, while DERM trades at $7.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas DERM's P/E ratio is -19.35. In terms of profitability, ACOR's ROE is +1.43%, compared to DERM's ROE of -0.52%. Regarding short-term risk, ACOR is more volatile compared to DERM. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs BIOA Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, BIOA has a market cap of 163.5M. Regarding current trading prices, ACOR is priced at $0.66, while BIOA trades at $4.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas BIOA's P/E ratio is -2.30. In terms of profitability, ACOR's ROE is +1.43%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, ACOR is more volatile compared to BIOA. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs THTX Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, THTX has a market cap of 144.8M. Regarding current trading prices, ACOR is priced at $0.66, while THTX trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas THTX's P/E ratio is -16.58. In terms of profitability, ACOR's ROE is +1.43%, compared to THTX's ROE of +0.16%. Regarding short-term risk, ACOR is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs IRWD Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, IRWD has a market cap of 122M. Regarding current trading prices, ACOR is priced at $0.66, while IRWD trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas IRWD's P/E ratio is -3.97. In terms of profitability, ACOR's ROE is +1.43%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, ACOR is more volatile compared to IRWD. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs SCTL Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ACOR is priced at $0.66, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ACOR's ROE is +1.43%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ACOR is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs PROC Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, PROC has a market cap of 114M. Regarding current trading prices, ACOR is priced at $0.66, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas PROC's P/E ratio is 1.53. In terms of profitability, ACOR's ROE is +1.43%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ACOR is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs CRDL Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, CRDL has a market cap of 107.4M. Regarding current trading prices, ACOR is priced at $0.66, while CRDL trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas CRDL's P/E ratio is -3.82. In terms of profitability, ACOR's ROE is +1.43%, compared to CRDL's ROE of -2.10%. Regarding short-term risk, ACOR is more volatile compared to CRDL. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs OPTN Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ACOR is priced at $0.66, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ACOR's ROE is +1.43%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, ACOR is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs ZOM Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ACOR is priced at $0.66, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ACOR's ROE is +1.43%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, ACOR is more volatile compared to ZOM. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs GRVI Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ACOR is priced at $0.66, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ACOR's ROE is +1.43%, compared to GRVI's ROE of +0.28%. Regarding short-term risk, ACOR is more volatile compared to GRVI. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs INCR Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, INCR has a market cap of 73.1M. Regarding current trading prices, ACOR is priced at $0.66, while INCR trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas INCR's P/E ratio is -3.60. In terms of profitability, ACOR's ROE is +1.43%, compared to INCR's ROE of -0.07%. Regarding short-term risk, ACOR is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs ZYNE Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ACOR is priced at $0.66, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ACOR's ROE is +1.43%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ACOR is more volatile compared to ZYNE. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs SSIC Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ACOR is priced at $0.66, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ACOR's ROE is +1.43%, compared to SSIC's ROE of +0.09%. Regarding short-term risk, ACOR is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs ASRT Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, ASRT has a market cap of 66.2M. Regarding current trading prices, ACOR is priced at $0.66, while ASRT trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas ASRT's P/E ratio is -2.16. In terms of profitability, ACOR's ROE is +1.43%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, ACOR is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs VLNS Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ACOR is priced at $0.66, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ACOR's ROE is +1.43%, compared to VLNS's ROE of N/A. Regarding short-term risk, ACOR is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs QNTM Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, QNTM has a market cap of 54M. Regarding current trading prices, ACOR is priced at $0.66, while QNTM trades at $18.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas QNTM's P/E ratio is -1.40. In terms of profitability, ACOR's ROE is +1.43%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, ACOR is more volatile compared to QNTM. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs JUPW Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ACOR is priced at $0.66, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ACOR's ROE is +1.43%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, ACOR is more volatile compared to JUPW. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs EGRX Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, EGRX has a market cap of 46M. Regarding current trading prices, ACOR is priced at $0.66, while EGRX trades at $3.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas EGRX's P/E ratio is 4.18. In terms of profitability, ACOR's ROE is +1.43%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, ACOR is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs CPIX Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, CPIX has a market cap of 45M. Regarding current trading prices, ACOR is priced at $0.66, while CPIX trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas CPIX's P/E ratio is -12.55. In terms of profitability, ACOR's ROE is +1.43%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, ACOR is more volatile compared to CPIX. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs QLI Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ACOR is priced at $0.66, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas QLI's P/E ratio is -4.92. In terms of profitability, ACOR's ROE is +1.43%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ACOR is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs RMTI Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, RMTI has a market cap of 38.6M. Regarding current trading prices, ACOR is priced at $0.66, while RMTI trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas RMTI's P/E ratio is -113.00. In terms of profitability, ACOR's ROE is +1.43%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, ACOR is more volatile compared to RMTI. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs KALA Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, KALA has a market cap of 38.1M. Regarding current trading prices, ACOR is priced at $0.66, while KALA trades at $5.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas KALA's P/E ratio is -0.80. In terms of profitability, ACOR's ROE is +1.43%, compared to KALA's ROE of -3.69%. Regarding short-term risk, ACOR is more volatile compared to KALA. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs HEXO Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ACOR is priced at $0.66, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ACOR's ROE is +1.43%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ACOR is more volatile compared to HEXO. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs SCYX Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, SCYX has a market cap of 27.4M. Regarding current trading prices, ACOR is priced at $0.66, while SCYX trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas SCYX's P/E ratio is -1.26. In terms of profitability, ACOR's ROE is +1.43%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, ACOR is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs CYTH Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ACOR is priced at $0.66, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ACOR's ROE is +1.43%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, ACOR is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs IXHL Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, IXHL has a market cap of 20.6M. Regarding current trading prices, ACOR is priced at $0.66, while IXHL trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas IXHL's P/E ratio is -0.18. In terms of profitability, ACOR's ROE is +1.43%, compared to IXHL's ROE of -2.03%. Regarding short-term risk, ACOR is more volatile compared to IXHL. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs DRRX Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, DRRX has a market cap of 19.1M. Regarding current trading prices, ACOR is priced at $0.66, while DRRX trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas DRRX's P/E ratio is -1.28. In terms of profitability, ACOR's ROE is +1.43%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, ACOR is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs PRPH Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, PRPH has a market cap of 17.6M. Regarding current trading prices, ACOR is priced at $0.66, while PRPH trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas PRPH's P/E ratio is -0.19. In terms of profitability, ACOR's ROE is +1.43%, compared to PRPH's ROE of -1.65%. Regarding short-term risk, ACOR is more volatile compared to PRPH. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs GELS Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, GELS has a market cap of 17.4M. Regarding current trading prices, ACOR is priced at $0.66, while GELS trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas GELS's P/E ratio is -7.67. In terms of profitability, ACOR's ROE is +1.43%, compared to GELS's ROE of -0.07%. Regarding short-term risk, ACOR is more volatile compared to GELS. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs FLGC Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, FLGC has a market cap of 15.5M. Regarding current trading prices, ACOR is priced at $0.66, while FLGC trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas FLGC's P/E ratio is -0.71. In terms of profitability, ACOR's ROE is +1.43%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, ACOR is more volatile compared to FLGC. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs ACRX Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ACOR is priced at $0.66, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ACOR's ROE is +1.43%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, ACOR is more volatile compared to ACRX. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs COSM Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, COSM has a market cap of 14M. Regarding current trading prices, ACOR is priced at $0.66, while COSM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas COSM's P/E ratio is -0.44. In terms of profitability, ACOR's ROE is +1.43%, compared to COSM's ROE of -0.51%. Regarding short-term risk, ACOR is more volatile compared to COSM. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs TXMD Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, TXMD has a market cap of 13.7M. Regarding current trading prices, ACOR is priced at $0.66, while TXMD trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas TXMD's P/E ratio is -6.21. In terms of profitability, ACOR's ROE is +1.43%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, ACOR is more volatile compared to TXMD. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs AYTU Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, AYTU has a market cap of 13.5M. Regarding current trading prices, ACOR is priced at $0.66, while AYTU trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas AYTU's P/E ratio is -1.47. In terms of profitability, ACOR's ROE is +1.43%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, ACOR is more volatile compared to AYTU. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs TLPH Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, TLPH has a market cap of 10.6M. Regarding current trading prices, ACOR is priced at $0.66, while TLPH trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas TLPH's P/E ratio is -1.17. In terms of profitability, ACOR's ROE is +1.43%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, ACOR is more volatile compared to TLPH. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs AGRX Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ACOR is priced at $0.66, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ACOR's ROE is +1.43%, compared to AGRX's ROE of +0.93%. Regarding short-term risk, ACOR is more volatile compared to AGRX. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs SBFMW Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, SBFMW has a market cap of 9.1M. Regarding current trading prices, ACOR is priced at $0.66, while SBFMW trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas SBFMW's P/E ratio is -0.13. In terms of profitability, ACOR's ROE is +1.43%, compared to SBFMW's ROE of -0.21%. Regarding short-term risk, ACOR is more volatile compared to SBFMW. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs EVOK Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, EVOK has a market cap of 9.1M. Regarding current trading prices, ACOR is priced at $0.66, while EVOK trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas EVOK's P/E ratio is -4.96. In terms of profitability, ACOR's ROE is +1.43%, compared to EVOK's ROE of -1.02%. Regarding short-term risk, ACOR is more volatile compared to EVOK. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs IMCC Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, IMCC has a market cap of 9M. Regarding current trading prices, ACOR is priced at $0.66, while IMCC trades at $2.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas IMCC's P/E ratio is -2.12. In terms of profitability, ACOR's ROE is +1.43%, compared to IMCC's ROE of -0.79%. Regarding short-term risk, ACOR is more volatile compared to IMCC. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs YCBD Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, YCBD has a market cap of 8.6M. Regarding current trading prices, ACOR is priced at $0.66, while YCBD trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas YCBD's P/E ratio is 0.01. In terms of profitability, ACOR's ROE is +1.43%, compared to YCBD's ROE of -0.01%. Regarding short-term risk, ACOR is more volatile compared to YCBD. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.
ACOR vs BFRI Comparison
ACOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACOR stands at 821K. In comparison, BFRI has a market cap of 8.4M. Regarding current trading prices, ACOR is priced at $0.66, while BFRI trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACOR currently has a P/E ratio of -0.00, whereas BFRI's P/E ratio is -1.10. In terms of profitability, ACOR's ROE is +1.43%, compared to BFRI's ROE of -2.16%. Regarding short-term risk, ACOR is more volatile compared to BFRI. This indicates potentially higher risk in terms of short-term price fluctuations for ACOR.